SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

XBIO

Xenetic Biosciences Inc.
NASDAQHealth Care

Latest close: 1.99 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Sep 23, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Sep 16, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  3. Aug 7, 2026Material event · 8-KFiled by the company itself.Open the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record4549 flagged findings
Reported transactions (Form 4)20since Dec 6, 2023 · and 1 other holding
Corporate events (8-K)30since Jul 22, 2019

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-05-12listing compliance noticerecentOpen filing ↗
    “…financings, corporate collaborations, related party funding, or other means to continue as a going concern, the terms, timing and…”
    +1 more passage from the same document
    • “…transaction on the Company’s current business operations, anticipated business strategy and product development plans; ·…”
  • 2026-03-12listing compliance noticerecentOpen filing ↗
    “…by the Company’s board of directors (the “Board”) and a special independent committee thereof, and risks related thereto; ·…”
    +1 more passage from the same document
    • “…on acceptable terms, or at all, may force us to delay, limit or terminate our product development efforts, other operations or…”
  • 2026-03-12capital return (buybacks/dividends)recentOpen filing ↗
    “…Information The information required by Item 5 with respect to securities authorized for issuance under equity compensation plans…”
  • 2026-03-12regulatory investigationrecentOpen filing ↗
    “…a license; · Suspend or hold any of our ongoing clinical trials; · Require additional clinical trials; · Refuse to approve pending…”
  • 2026-03-12Department of Justice inquiryrecentOpen filing ↗
    “…to form association health plans that would be allowed to provide coverage across state lines, increase the availability of…”

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

Reverse splits in 5 years

1 reverse split in 5 years (1:10 on May 15, 2023) · 1:10 cumulative

The other times: of 818 securities that did their first reverse split in 5 years, a year later the median was worth 0.53× the price on the day of the split; 382 lost more than half and 209 rose (809 with a price a year later).

Our own series, not the whole market: based on the splits we have on record (provider and SEC); an unrecorded one does not count. Historical distribution, not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 454)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Sep 23, 268-K ↗Current report · Communication to the market
  • Sep 18, 26SCHEDULE 13G ↗Passive stake
  • Sep 16, 268-K ↗Current report · Sold unregistered shares
  • Aug 7, 268-K ↗Current report · Results
  • Aug 6, 2610-Q ↗Quarterly report
  • May 29, 26SCHEDULE 13G ↗Passive stake · Michael Liu · 5.5% · event on May 22, 26
  • May 14, 26SCHEDULE 13G/A ↗Passive stake · Renaissance Technologies LLC · 6.0% · event on Mar 31, 26 · amendment
  • May 13, 268-K ↗Current report · Results
  • May 12, 2610-Q ↗Quarterly report
  • Apr 24, 2610-K/A ↗Annual report · amendment
  • Apr 24, 268-K ↗Current report · A senior executive left or was appointed
  • Apr 23, 26Form 4 ↗Insider transaction
  • Mar 13, 268-K ↗Current report · Results
  • Mar 12, 2610-K ↗Annual report
  • Feb 12, 26SCHEDULE 13G ↗Passive stake · Renaissance Technologies LLC · 7.8% · event on Oct 27, 25
  • Jan 9, 268-K ↗Current report · Other events
  • Insider transaction · 4 Form 4 filingsshow all 4hide
  • Dec 11, 25DEFA14A ↗Shareholder meeting and votes
  • Dec 11, 258-K ↗Current report · Communication to the market
  • Nov 13, 258-K ↗Current report · Results
  • Nov 12, 2510-Q ↗Quarterly report
  • Oct 31, 25DEFA14A ↗Shareholder meeting and votes

454 filings on record, the oldest from Nov 21, 11.

Listing the 25 most recent filings of the 454 on record.

8-Ks, explained

Stress7Structure48Governance32
  • Sep 16, 26StructureSold unregistered shares+3 more in the same filing8-K 3.02 ↗
  • Apr 24, 26GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Oct 14, 25StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Apr 10, 25GovernanceAuditor change filing (8-K Item 4.01)+1 more in the same filing8-K 4.01 ↗
  • Nov 7, 24StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Governance3 senior executive changes2024show all 3hide
    • Oct 31, 24GovernanceA senior executive left or was appointed8-K 5.02 ↗
    • Jun 21, 24GovernanceA senior executive left or was appointed8-K 5.02 ↗
    • May 22, 24GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Dec 2, 22StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Oct 12, 22StructureSold unregistered shares8-K 3.02 ↗
  • Jul 7, 22StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Jun 6, 22StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Apr 27, 22StructureSold unregistered shares+4 more in the same filing8-K 3.02 ↗
  • Nov 19, 21StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗

11 older filings not shown · The record reaches back to Feb 12, 13.

Notable in the record

Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.

  • Oct 30, 20StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Apr 24, 20StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Jul 2, 19StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Aug 14, 17StressListing notice (8-K 3.01)+2 more in the same filing8-K 3.01 ↗
  • Feb 12, 13StressRestructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗

The full record holds 7 stress filings.

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • Renaissance Technologies LLC6.0%Mar 31, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • Michael Liu5.5%May 22, 26SCHEDULE 13G ↗2 co-filers on this document — the figure is the largest single stake, not their sum.

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

No purchases or sales are on record in this stretch; only other transactions (compensation, withholding, exercises or gifts).

Stock compensation, tax and giftsshow the other transactionhide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Apr 21, 26Compensationamount n/aJAMES F PARSLOWInterim CEO and CFO↗

The full record holds 1 transactions and goes back to Dec 6, 23.

Its sector and its market

Xenetic Biosciences Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From Xenetic Biosciences Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow Xenetic Biosciences Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
Series with incidents in the period; the chart shows what could be kept.
SEC records
454 documents on file, from Nov 21, 2011 to Sep 23, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.